The Effect of Education and Telephone Follow-up Provided to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-Care Agency

The Effect of Education and Telephone Follow-up Provided to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-Care Agency | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article The Effect of Education and Telephone Follow-up Provided to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-Care Agency Gamze Alıncak, Ayşegül Koç This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7299984/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Objective: This study aimed to evaluate the effect of education and telephone follow-up provided to cancer patients receiving immunotherapy on symptom management and self-care agency. Methods: The data for this study were collected from the outpatient chemotherapy unit of an educational research hospital. The study sample consisted of cancer patients who agreed to participate in the study and who were receiving immunotherapy for the first time and exclusively (n=69). In the first phase of the study, interviews were conducted with 22 cancer patients receiving immunotherapy to develop the content of the educational booklet. Participants were divided into an intervention group (n=34) and a control group (n=35) using a randomization list. Participants in the intervention group received face-to-face education using the developed educational booklet and were followed up by telephone for three months. The control group received standard care. Participants in the intervention group were assessed twice after receiving the education: at the end of the first cycle and at the end of the third cycle. Demographic and medical characteristics were collected using a patient information form, telephone interview form, telephone interview evaluation form, Nightingale Symptom Assessment Scale, and Self-Care Agency Scale. Descriptive statistics, chi-square, t-test for independent samples, Mann Whitney U test to examine differences in scale scores between groups, and Wilcoxon matched-pairs test to examine differences in scale scores between measurement times were used to evaluate the data. Results: The intervention significantly enhanced self-care capacity among patients receiving immunotherapy (p < 0.05, G = 1.78). Moreover, physical and social well-being scores were significantly higher in the intervention group compared to controls (p < 0.05). Conclusions: Education and telephone follow-up provided to cancer patients receiving immunotherapy were found to be effective in increasing patients' self-care capacity and managing possible symptoms (p<0.05, G=1.78, G=0.55). Figures Figure 1 Introduction In recent years, studies aimed at understanding the relationship between the immune system and cancer have led to an increase in the use of cancer immunotherapy. 1 Immunotherapy, which is used in various types of metastatic cancer, has revolutionized cancer treatment with its lasting clinical results. 2 Today, there are numerous approved immunotherapy drugs for cancer treatment. These include immune checkpoint inhibitors (ICI), lymphocyte-regulating cytokines, chimeric antigen receptor therapy, and cancer vaccines. 1 , 2 Checkpoint inhibitors, which play a role in regulating the immune system, suppress the T cell response. This prevents autoimmunity and excessive inflammation, thereby maintaining homeostasis. 3 Tumor cells can use these immune checkpoints to suppress the T cell response and evade the immune system. At this stage, checkpoint inhibitors, whose clinical use is increasingly widespread, come into play. ICIs are used in various malignancies such as melanoma, lung cancer, and lymphoma. 4 ICIs, which eliminate tumor cells by regulating the immune response, can also cause immune-related adverse events (irAEs) that can affect many organs. These side effects may manifest as fatigue, itching, rash, redness, diarrhea, nausea, headache, and others. 5 , 6 , 7 The timing of side effects varies depending on the affected organ and the type of treatment. Side effects may appear as early as the day after a single dose of medication or may occur weeks to months later. 8 , 9 If these immune-related adverse events are not detected and managed early, they may lead to discontinuation of treatment and initiation of immunosuppressive therapy. Therefore, it is essential to identify the symptoms observed in patients receiving ICI therapy to strengthen symptom management. 10 A study evaluating the suitability, readability, quality, and usefulness of online resources for cancer patients receiving immunotherapy noted that there is a lack of resources to support patients in learning to manage immunotherapy side effects on their own. Additionally, brochures or booklets were found to be superior to web pages in terms of suitability and quality. 11 A qualitative study by Lai Kwon and colleagues on metastatic non-small cell lung cancer patients receiving immunotherapy identified unmet needs such as difficulties in managing treatment side effects and toxicity. 12 A review of the literature reveals that there are limited studies on symptom management in cancer patients receiving immune checkpoint inhibitor therapy. 13 , 14 For this reason, our study collected qualitative data from cancer patients only receiving checkpoint inhibitors to perform a needs analysis. An educational booklet was created based on the identified needs.This is because no studies evaluating symptoms and self-care agency in cancer patients receiving only immunotherapy have been found in the literature. Accordingly, this study aimed to determine the effect of education and telephone follow-ups provided to cancer patients receiving immune checkpoint inhibitor therapy on symptom management and self-care agency. Study Purpose The purpose of the study is to evaluate the effect of education and telephone follow-up provided to cancer patients who will receive checkpoint inhibitor treatment for the first time on symptom management and self-care agency. Methods Design It is a randomized controlled trial designed by CONSORT (Consolidated Standards of Reporting Trials) recommendations, with a follow-up period of three months. 15 Trial registration: ClinicalTrials.gov NCT05683652. Participants The study was conducted in the outpatient chemotherapy unit of an educational research hospital in Turkey. Data for the study were collected between April 2022 and April 2023. The eligibility criteria were as follows: able to read and write Turkish, no psychiatric diagnosis that would impair comprehension, no physical impairment in hearing or speech that would prevent telephone communication, aware of receiving immunotherapy, receiving ICI therapy for the first time and only, aged 18–90, willing and eager to participate in the study, and participants who gave written and verbal consent to participate in the study. Exclusion criteria include: participants who wish to withdraw from the study, participants who cannot be reached or with whom communication is not possible, participants who die during the study, participants who receive radiotherapy or chemotherapy in addition to immunotherapy during the study, and participants who discontinue immunotherapy and switch to radiotherapy, chemotherapy, or other treatments. Study procedure During the preparatory phase of the study, qualitative data was collected from patients only receiving ICI treatment. The purpose of conducting qualitative interviews was to establish the theoretical framework of the educational booklet based on patient experiences. Face-to-face interviews with 22 cancer patients receiving only ICI treatment were recorded and transcribed into written text by the researcher using Microsoft Office Word without any comments or additions. The data obtained were analyzed by the consultant and researcher using content analysis. After the data converted into written text were read repeatedly, the statements were coded. Thematic coding was performed on the responses to create main themes and subthemes. The themes and subthemes created were evaluated by obtaining expert opinion. A total of 3 main themes and 11 sub-themes were created. Here, the educational booklet was evaluated by experts according to the DISCERN (Quality Criteria for Consumer Health Information) scale in terms of content, appropriateness, reliability, and information quality, and the necessary adjustments were made. Randomization and Blinding After providing written informed consent, participants were assigned to the intervention and control groups according to the randomization list. The group assignment of participants was determined digitally (via WhatsApp) by a clerk responsible for treatment planning at the clinic, who was unaware of the study, based on the order of patient arrival. Due to the nature of the study, which included education and telephone follow-up, blinding of the researchers and participants was not possible. Data entry and analysis were performed by a statistician, and blinding was performed in the statistical analysis because the groups were only identified by numbers. Additionally, to prevent patient interaction, nurses working at the outpatient clinic were informed about the study, and patients in the intervention and control groups included in the study were treated on different days. Outcome Measures Demographic and Medical Characteristics and Patient Information Form The medical and demographic characteristics of patients were determined using a patient information form consisting of a total of eight questions prepared by the literature. 16 , 17 Telephone Interview Form The researcher's telephone number was provided to participants in the intervention group so that they could contact the researcher when needed. No special line was set up for the study. Participants were informed that they could contact the researcher 24/7, and no time restrictions were imposed. The form includes the date of the conversation with the patient/relative, the reason for the conversation, its duration, the symptoms experienced, and recommendations. 18 Telephone Interview Evaluation Form This form was prepared for the purpose of evaluating telephone interviews conducted with participants in the intervention group. 18 The form, consisting of a total of five items, was administered to the intervention group at the end of the third session. Nightingale Symptom Assessment Scale (N-SAS) The scale is a well-being scale developed for cancer patients. In this study, it was used to identify symptoms developed by cancer patients undergoing immunotherapy about their disease and treatment. The scale is a five-point likert scale, where responses to the evaluated item are scored as “0” for “no,” “1” for “very little,” “2” for “some,” “3” for “quite a bit,” and ‘4’ for “very much.” A high score on the scale indicates that the patient is highly affected by disease/treatment-related problems, while low scores indicate that patients have low overall quality of life and well-being in terms of subdimensions. 19 In the study, the Cronbach's alpha reliability coefficient of the scale was found to be 0.90. Self-Care Agency Scale (SCAS) The scale focuses on individuals' self-assessments of their engagement in self-care activities. The scale consists of 35 items, each of which is scored from 0 to 4. The response options are as follows: “Does not describe me at all” is scored as 0, “Does not describe me much” is scored as 1, “I don't know” is scored as 2, “Describes me a little” is scored as 3, and “Describes me very much” is scored as 4. 20 In our study, the Cronbach alpha reliability coefficient of the scale was found to be 0.95. Data Collection Procedure Participants were selected based on inclusion and exclusion criteria and were provided with detailed information about the study. Participants were asked to sign a written informed consent form. Each participant was assigned a numerical code. Patients in the intervention group were contacted according to a list generated by Random.org, and an appointment was scheduled one hour before their first immunotherapy session. The interviews were conducted in a quiet, isolated room with a table and chairs, which was a passive area within the unit where there was no patient flow. Patients and their relatives were included in the training. The training sessions lasted an average of 40–50 minutes. Patients in the intervention group who received training were followed up by telephone by the researcher within one week after each course. During the telephone calls, symptom monitoring was performed, and coping strategies for reported symptoms were reviewed. Routine clinical procedures were applied to patients in the control group. The first measurements for patients in both groups were taken in person on the day they came for their second course of treatment, and the second measurements were taken in person after the third course of treatment was completed. Statistical Methods All data were analyzed using IBM SPSS Statistics version 23.0 (IBM Corp Armonk, NY). The number, percentage, mean, standard deviation, and chi-square test were used to evaluate the participants' demographic and medical characteristics. The t-test for independent samples was used to determine the difference between groups according to age. The Mann-Whitney U test was used to determine whether there were differences between groups in terms of N-SAS and SCAS scores, and the Wilcoxon matched-pairs test was used to determine differences between measurement times for N-SAS and SCAS scores. Cohen's d values were used to interpret the effect size (G) of the education provided and telephone follow-up. 21 P < .05 was considered statistically significant. Ethical Considerations This study was approved by the Ethics Committee of Ankara Yıldırım Beyazıt University Faculty of Social and Human Sciences (E-84892257-300-100327). After the necessary explanations about the study were made to the participants included in the study, both verbal and written consent forms were obtained from all participants in accordance with the Declaration of Helsinki. Results A total of 74 participants were screened. Two participants who met the sample criteria declined to participate in the study, so 72 participants were randomized. One participant from the control group and one participant from the intervention group were excluded. One participant was also excluded from the study because radiotherapy was added to their treatment. The study was completed with a total of 69 participants, 34 in the intervention group and 35 in the control group. Participants’ Characteristics There was no statistically significant difference between the intervention and control groups in terms of personal and medical information. The groups were found to be homogeneously distributed (Table 1). The participants most commonly had a diagnosis of lung cancer, had previously undergone chemotherapy, were in stage IV, and had hypertension as the most common accompanying chronic disease (Table 1). Effects of the Intervention All participants in the intervention group reported satisfaction with the telephone calls and stated that the calls helped them cope with the side effects of immunotherapy (Table 2). The most common symptoms reported by participants in the intervention group following telephone follow-up were fatigue, constipation, itching, dry mouth, dry skin, decreased appetite, and coughing (Table 3). Table 4 shows that the median self-care strength value measured at the end of the third cycle was 115.0 (103-121) in the intervention group and 75.0 (63-90) in the control group, and the difference between the two groups was statistically significant (p<0.05). When looking at the median values, the median value of SCAS in the intervention group was higher than that in the control group. This indicates that the self-care agency of participants in the intervention group was at a better level than that of the control group at the end of the third cycle. The effect of the education and telephone follow-up applied to the intervention group on self-care agency at the second measurement (end of the third session) was found to be strong (G=1.78). The median value of the N-SAS physical well-being subscale score for the intervention group was 0.08 (0-0.20), while the median value of the N-SAS physical well-being subscale score for the control group was 0.30 (0.20-0.65), and the difference between the two was statistically significant (p<0.05). When looking at the median values, the median value of the physical well-being subscale score in the control group is higher than that in the intervention group. This indicates that the physical well-being of the participants in the intervention group was at a better level than that of the control group at the end of the third session. The education and telephone follow-up applied to the intervention group were found to have a strong effect on physical well-being at the second measurement (end of the third session) (G=1.03). The median value of the N-SAS social well-being subscale score for the intervention group was 0 (0-0), while the median value of the N-SAS social well-being subscale score for the control group was 0.13 (0-0.25), and the difference between the two was statistically significant (p<0.05). When looking at the median values, the median value of the social well-being subscale score of the control group is higher than that of the intervention group. This indicates that the social well-being of the participants in the intervention group was at a better level than that of the control group at the end of the third session. It was determined that the education and telephone follow-up applied to the intervention group had a strong effect on social well-being at the second measurement (end of the third session) (G = 0.86). The median value of the N-SAS psychological well-being subscale score for the intervention group was 0.20 (0-0.70), while the median value of the N-SAS psychological well-being subscale score for the control group was 0.40 (0-0.90), and the difference between the two was not statistically significant (p>0.05). The median value of the N-SAS score for the intervention group was 0.14 (0.04-0.28), while the median value of the N-SAS score for the control group was 0.34 (0.17-0.58), and the difference between the two was statistically significant (p<0.05). When looking at the median values, the median value of the N-SAS score in the control group is higher than that in the intervention group. This indicates that the participants in the intervention group had a better level of general well-being at the end of the third session compared to the control group. The education and telephone follow-up applied to the intervention group were found to have a moderate effect on general well-being at the second measurement (end of the third session) (G=0.55). Discussion Reviews and guidelines on cancer patients receiving immunotherapy in the literature indicate that patients should be informed about possible side effects and that early detection and reporting of these side effects is important for symptom. 22 , 23 , 24 In an observational retrospective study evaluating nurse-led telephone follow-up over a six-month period for palliative care patients with advanced cancer, it was determined that telephone follow-up can be effective for patients and their families by improving symptom control. 25 In line with the literature, this study found that the education and telephone follow-up provided to the intervention group improved participants' physical and social well-being. The significant difference observed in the physical well-being subscale may be related to the fact that the educational content focused more on the management of physical symptoms. Based on the feedback from participants in the intervention group who received telephone follow-up, it appears that simply calling them and asking about their well-being made them happy and suggests that the social well-being of participants in the intervention group was at a higher level than that of the control group. Furthermore, it is thought that the lack of focus on the management of psychological symptoms in the educational content provided to the intervention group did not create a statistically significant difference between the groups in terms of psychological well-being and had a weak effect. In a study examining the effect of education provided to patients undergoing inpatient treatment for laryngeal cancer on self-care agency, it was noted that the group that received education had a better level of self-care agency. 26 Another study examining the effect of web-based education on self-care behaviors and social adjustment in cancer patients determined that the education provided could improve patients' self-care agency and self-management behaviors. 27 In this study, it is thought that the education and telephone follow-up applied to the intervention group increased the participants' self-care capacity and that the education provided during the telephone follow-ups after the face-to-face education created a significant difference between the first and second measurements due to the repetition of the education when necessary. Study limitations The study was limited by the fact that it was conducted in a specific patient group that only received immune checkpoint inhibitors, the number of patients who would only receive ICIs was small, losses occurred in the sample group during the study, and the fact that randomization could not be double-blind due to the nature of the study. Conclusion It was determined that the effect of education and telephone monitoring given to cancer patients receiving immunotherapy on self-care capacity was at a strong level, and its effect on symptom management was at a medium level. Therefore, telephone monitoring together with education in patients receiving immune checkpoint inhibitors has an effect on both symptom management and increasing self-care agency. Declarations Author Contribution AUTHOR CONTRIBUTIONSGamze ALINCAK: Data curation, Formal analysis, Writing- original draft, Investigation, Ayşegül KOÇ: Formal analysis, Writing- original draft, Investigation, Funding Declarations The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. References Gupta, S., Gupta, S. C., Hunter, K. D., & Pant, A. B. (2020). Immunotherapy: a new hope for cancer patients. Journal of Oncology , 3548603. Zhang, Y., & Zhang, Z. (2020). The history and advances in cancer immunotherapy: understanding the characteristics of tumor‑infiltrating immune cells and their therapeutic implications. Cellular & Molecular Immunology , 17(8), 807‑821. Passarelli, A., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F. (2017). Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget , 8(62), 106132. Bagchi, S., Yuan, R., & Engleman, E. G. (2021). Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annual Review of Pathology , 16, 223–249. Kennedy, L. B., & Salama, A. K. (2020). A review of cancer immunotherapy toxicity. CA: A Cancer Journal for Clinicians , 70(2), 86–104. Arnaud‑Coffin, P., Maillet, D., Gan, H. K., Stelmes, J. J., You, B., Dalle, S., & Péron, J. (2019). A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. International Journal of Cancer , 145(3), 639‑648. Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., & Hallmeyer, S. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology , 36(17), 1714. Durrechou, Q., Domblides, C., Sionneau, B., Lefort, F., Quivy, A., Ravaud, A., Gross‑Goupil, M., & Daste, A. (2020). Management of immune checkpoint inhibitör toxicities. Cancer Management and Research , 9139‑9158. Sznol, M., Postow, M. A., Davies, M. J., Pavlick, A. C., Plimack, E. R., Shaheen, M., Veloski, C., & Robert, C. (2017). Endocrine‑related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treatment Reviews , 58, 70‑76. Feng, L. N., He, J., Feng, L. X., Li, Y., Li, J., & Chen, C. (2023). Symptoms, symptom clusters and associated factors among cancer patients receiving immune checkpoint inhibitor therapy: A cross-sectional survey. European Journal of Oncology Nursing , 63, 102288. Nicolas‑Joseph, M., Brahim, L. O., Boureanu, M. I., Frati, F. Y., Bourdache, L. R., Belzile, E., & Lambert, S. D. (2023). An evaluation of the suitability, readability, quality, and usefulness of online resources for patients with cancer receiving immunotherapy. Patient Education and Counseling , 110, 107640. Lai‑Kwon, J., Heynemann, S., Flore, J., Dhillon, H., Duffy, M., Burke, J., … Jefford, M. (2021). Living with and beyond metastatic non‑small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. Journal of Cancer Survivorship , 15, 392‑397. Glaser, S. L. C., Fraterman, I., van Brummelen, N., Tibollo, V., Del Campo, L. M., Mallo, H., … Medlock, S. (2025). Usability and Usefulness of a Symptom Management Coaching System for Patients With Cancer Treated With Immune Checkpoint Inhibitors: Comparative Mixed Methods Study. JMIR Formative Research , 9, e57659. Kutzleben, M. V., Galuska, J. C., Hein, A., Griesinger, F., & Ansmann, L. (2022). Needs of Lung Cancer Patients Receiving Immunotherapy and Acceptance of Digital and Sensor-Based Scenarios for Monitoring Symptoms at Home—A Qualitative‑Explorative Study. International Journal of Environmental Research and Public Health , 19(15), 9265. Gewandter, J. S., Eisenach, J. C., Gross, R. A., et al. (2019). Checklist for the preparation and review of pain clinical trial publications: a pain-specific supplement to CONSORT. Pain Reports , 4(3):38–40. Ream, E., Hughes, A. E., Cox, A., Skarparis, K., Richardson, A., Pedersen, V. H., & Bryant, A. (2020). Telephone interventions for symptom management in adults with cancer. Cochrane Database of Systematic Reviews , 6. Tatokoro, M., & Matsuo, N. (2022). The Impact of Aging on Symptom Prevalence and Management in Terminally ill Patients With Cancer. Journal of Pain and Symptom Management , 63(2), 251‑259. Ökten, Ç. (2017). Kemoterapi uygulanan kolorektal kanserli hastalarda orem öz bakım eksikliği kuramına temellendirilmiş eğitimin ve telefonla izlemin öz bakım gücü, kaygı, yalnızlık ve iyilik hallerine etkisi (Doktora tezi). Akdeniz Üniversitesi. Can, G., Erol, O., Aydiner, A., & Topuz, E. (2011). Non-pharmacological interventions used by cancer patients during chemotherapy in Turkey. European Journal of Oncology Nursing , 15(2), 178–184. Nahcivan, N. O. (2004). A Turkish language equivalence of the exercise of self-care agency scale. Western Journal of Nursing Research , 26(7), 813‑824. Berk, İ. (2019). Meta Analizi: Paralel Kontrollü Çalışmalarda Bir Uygulama (Yüksek Lisans Tezi). Afyon Kocatepe Üniversitesi. Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., & Davies, M. J. (2021). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Journal of Clinical Oncology , 39(36), 4073‑4126. Wood, L. S., Moldawer, N. P., & Colleen Lewis, M. S. N. (2019). Immune checkpoint inhibitor therapy. Clinical Journal of Oncology Nursing , 23(3), 271‑280. Zhang, L., & Lu, Y. (2021). Follow-up care for patients receiving immune checkpoint inhibitors. Asia‑Pacific Journal of Oncology Nursing , 8(6), 596‑603. Valenti, V., Rossi, R., Scarpi, E., Ricci, M., Pallotti, M. C., Dall’Agata, M., Montalti, S., & Maltoni, M. (2023). Nurse‑led telephone follow‑up for early palliative care patients with advanced cancer. Journal of Clinical Nursing , 32(11‑12), 2846‑2853. Fırat, S., & Öztunç, G. (2019). Total larenjektomili hastalara verilen eğitimin öz bakım gücüne etkisi. Çukurova Medical Journal , 44(3), 911‑921. Feng, L., Wang, W., Wu, M., & Ma, H. (2021). Effect of WeChat‐Based Health Education Combined with Satir Model on Self‐Management Behaviors and Social Adaptation in Colorectal Cancer Patients during the Perioperative Period. Journal of Healthcare Engineering , 2021 (1), 2701039. Tables Table 1. Group Comparison of Demographic and Medical Characteristics of Participants in the Intervention and Control Groups Table 2. Distribution of Responses of Participants in the Intervention Group to the Telephone Interview Evaluation Form Telephone Interview Evaluation Form Intervention Group (n=34) n % How phone calls can help you cope with immunotherapy side effects Yes it helped 34 100,0 Satisfaction with phone calls Yes, I'm satisfied. 34 100,0 There is a situation that prevents you from making a phone call. Yes it happened. 2 5,9 No it didn't happen. 32 94,1 Visiting any healthcare institution other than routine check-ups due to immunotherapy-related side effects in the last 3 months Yes I applied 9 26,5 No I did not apply 25 73,5 Reason for applying to the health institution for applicants Bloody sputum 1 11,1 Pain and swelling in joints 1 11,1 Chest pain 1 11,1 Cough, Fatigue 1 11,1 Cough, Dispnea 1 11,1 Increased fever 1 11,1 Dizziness, Vomiting 1 11,1 Tingling in the fingers 1 11,1 Forgetfulness, absent-mindedness, inability to form sentences 1 11,1 What happened to the applicants? Hospitalization drug therapy 4 44,4 Rheumatology Polyclinic 1 11,2 Emergency Unit 2 22,2 Neurology Polyclinic 2 22,2 Table3 .Distribution of symptoms determined by telephone in the intervention group Intervention Group (n = 34) Symptom Yes No n % n % Fatigue 24 70,6 10 29,4 Constipation 14 41,2 20 58,8 Itching 13 38,2 21 61,8 Dryness on the mouth 11 32,4 23 67,6 Skin dryness 9 26,5 25 73,5 Loss appetite 7 20,6 27 79,4 Cough 5 14,7 29 85,3 Shortness of breath 3 8,8 31 91,2 Vomiting 3 8,8 31 91,2 Exchange of taste 3 8,8 31 91,2 Redness on the skin 2 5,9 32 94,1 Redness of the eye 2 5,9 32 94,1 High fever 2 5,9 32 94,1 Diarrhea 1 2,9 33 97,1 Bloody sputum 1 2,9 33 97,1 Swelling in the joints 1 2,9 33 97,1 Increase Blood pressure 1 2,9 33 97,1 Night sweating 1 2,9 33 97,1 Jaundice in the hands 1 2,9 33 97,1 Chest pain 1 2,9 33 97,1 Tingle 1 2,9 33 97,1 Table 4. Comparison of Self-Care Abilities Scale and Nightingale Symptom Assessment Scale (N-SAS) and Sub-Dimension Scores of Groups According to the Second Measurement Time Scales and Subdimensions Group Min. Maks. SS Median 95,0% CL Quarterly Slice Z 1 p G Cohen’s d Lower-Upper 25-75p Self Care Agency Scale Experimental 66 134 111,2 15,8 115 113,00-119,00 103,00-121,00 -5,46 <0,001* 1,78 Strongly Control 41 125 77,4 21,7 75 67,00-83,00 63,00-90,00 N-SAS Physical Well-Being Experimental 0 0,95 0,16 0,21 0,08 0,05-0,15 0-0,20 -4,23 <0,001* 1,03 Strongly Control 0 1,5 0,44 0,33 0,3 0,25-0,65 0,20-0,65 N-SAS Social Well-Being Experimental 0 0,38 0,04 0,09 0 - 0-0 -3,38 <0,001* 0,86 Strongly Control 0 0,75 0,18 0,2 0,13 0-0,25 0-0,25 N-SAS Psychological Well-Being Experimental 0 2,8 0,52 0,77 0,2 0-0,40 0-0,70 -1,24 0,216 0,2 Weakly Control 0 3,2 0,67 0,79 0,4 0,30-0,90 0-0,90 Nightingale Symptom Assessment Scale (N-SAS) Experimental 0 1,22 0,24 0,31 0,14 0,08-0,18 0,04-0,28 -2,98 0,003* 0,55 Moderately Control 0,03 1,82 0,43 0,39 0,34 0,22-0,52 0,17-0,58 **p<0.05; Z1: Mann Whitney U test, 95% CI Lower-Upper: Lower limit-Upper limit in the 95% confidence interval; Quartile, 25-75p: 25th and 75th quartiles, G: Effect Size Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7299984","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":529154374,"identity":"9030f32b-cca5-4725-869b-c5cf55d0326d","order_by":0,"name":"Gamze Alıncak","email":"data:image/png;base64,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","orcid":"","institution":"Ankara Medipol University","correspondingAuthor":true,"prefix":"","firstName":"Gamze","middleName":"","lastName":"Alıncak","suffix":""},{"id":529154375,"identity":"62852c0e-223b-47c4-9216-96a7310a4957","order_by":1,"name":"Ayşegül Koç","email":"","orcid":"","institution":"Ankara Yıldırım Beyazıt University","correspondingAuthor":false,"prefix":"","firstName":"Ayşegül","middleName":"","lastName":"Koç","suffix":""}],"badges":[],"createdAt":"2025-08-05 11:23:05","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7299984/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7299984/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":93610314,"identity":"533d4873-52cd-422b-91eb-cab0072dcbcb","added_by":"auto","created_at":"2025-10-15 16:09:45","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":39834,"visible":true,"origin":"","legend":"","description":"","filename":"Fgure.docx","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/211243eb9516041ab6f90e6e.docx"},{"id":93612334,"identity":"1f738b8b-45f2-460c-af2a-3545eb2eaca4","added_by":"auto","created_at":"2025-10-15 16:17:45","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":62357,"visible":true,"origin":"","legend":"","description":"","filename":"Manuscript..docx","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/5f7c12b8850822eabdf76bdb.docx"},{"id":93613296,"identity":"4ec137fb-773f-417b-9961-a156bdd396d6","added_by":"auto","created_at":"2025-10-15 16:25:45","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":43823,"visible":true,"origin":"","legend":"","description":"","filename":"Tables.docx","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/53543f5a681f2812a625df61.docx"},{"id":93610316,"identity":"3a9dc2e7-703b-4187-a54e-08d3842ce4a0","added_by":"auto","created_at":"2025-10-15 16:09:45","extension":"json","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":4778,"visible":true,"origin":"","legend":"","description":"","filename":"a6c1c06e9fc94104b0ca87cad3dcdcb4.json","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/22c21c4d41a717b123266bb9.json"},{"id":93613834,"identity":"40adf649-581f-4e10-9b03-487ac2a828af","added_by":"auto","created_at":"2025-10-15 16:33:45","extension":"xml","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":127034,"visible":true,"origin":"","legend":"","description":"","filename":"a6c1c06e9fc94104b0ca87cad3dcdcb41enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/ce23ff06186070fa1601a6ff.xml"},{"id":93610318,"identity":"ee31dbea-0e91-42eb-b098-be5c1c7fbdc3","added_by":"auto","created_at":"2025-10-15 16:09:45","extension":"eps","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":592,"visible":true,"origin":"","legend":"","description":"","filename":"drawingimage1.eps","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/1d5a54b7ae88a59e03f1ea98.eps"},{"id":93612335,"identity":"dcef8814-b4c7-4e73-a833-e53b1f16f573","added_by":"auto","created_at":"2025-10-15 16:17:45","extension":"eps","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":58690,"visible":true,"origin":"","legend":"","description":"","filename":"drawingimage10.eps","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/276c321a0f97ec3a272a7cb6.eps"},{"id":93612336,"identity":"5b20cfff-ff79-4036-90b6-82acec20a280","added_by":"auto","created_at":"2025-10-15 16:17:45","extension":"eps","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":63991,"visible":true,"origin":"","legend":"","description":"","filename":"drawingimage11.eps","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/fabe032c2c802c5542228027.eps"},{"id":93610320,"identity":"37785493-45ed-4cfb-9b00-9e24fe1403d2","added_by":"auto","created_at":"2025-10-15 16:09:45","extension":"eps","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":589,"visible":true,"origin":"","legend":"","description":"","filename":"drawingimage12.eps","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/1a4ec3fadd467ca9278ae6b8.eps"},{"id":93612338,"identity":"83d2b829-9f80-4912-b4f5-49e0177e6229","added_by":"auto","created_at":"2025-10-15 16:17:45","extension":"eps","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":85393,"visible":true,"origin":"","legend":"","description":"","filename":"drawingimage2.eps","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/d8ab2b2310faa5feae266878.eps"},{"id":93610323,"identity":"26ddfa59-58a6-4dc1-8288-17902c7ac39d","added_by":"auto","created_at":"2025-10-15 16:09:45","extension":"eps","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":543,"visible":true,"origin":"","legend":"","description":"","filename":"drawingimage4.eps","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/160ed0358895dc475fd6f64a.eps"},{"id":93613833,"identity":"f06d175e-b20c-4f62-9bb9-cf0ef1a5d52b","added_by":"auto","created_at":"2025-10-15 16:33:45","extension":"eps","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":65968,"visible":true,"origin":"","legend":"","description":"","filename":"drawingimage6.eps","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/c266d19903398b2d454d117d.eps"},{"id":93612340,"identity":"c590d853-9e53-4ae8-ac42-4706e0545ec6","added_by":"auto","created_at":"2025-10-15 16:17:45","extension":"eps","order_by":14,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":542,"visible":true,"origin":"","legend":"","description":"","filename":"drawingimage7.eps","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/783a4a8382aa8e3090ad53d1.eps"},{"id":93613302,"identity":"0e7010d7-3dbc-4321-b423-ffc99bfcd930","added_by":"auto","created_at":"2025-10-15 16:25:45","extension":"eps","order_by":15,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":597,"visible":true,"origin":"","legend":"","description":"","filename":"drawingimage8.eps","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/44a4bf9e389d6df9b85815c2.eps"},{"id":93610329,"identity":"0ebc0cde-99ac-496f-8356-bac565cb8d0e","added_by":"auto","created_at":"2025-10-15 16:09:45","extension":"eps","order_by":16,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":604,"visible":true,"origin":"","legend":"","description":"","filename":"drawingimage9.eps","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/4787906827175f588206af2a.eps"},{"id":93610338,"identity":"6a374993-9b2b-4214-8935-7ca5474b89e8","added_by":"auto","created_at":"2025-10-15 16:09:46","extension":"jpeg","order_by":17,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":158309,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/9b9d4402b7713326fd3881f5.jpeg"},{"id":93612345,"identity":"71d50e46-7afe-40d2-a54d-a3c298036c37","added_by":"auto","created_at":"2025-10-15 16:17:45","extension":"jpeg","order_by":18,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1074,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/be94b0277ddab556639b62e5.jpeg"},{"id":93613298,"identity":"feda7733-51bc-4a6b-a1a1-9eb7e4f7c893","added_by":"auto","created_at":"2025-10-15 16:25:45","extension":"png","order_by":19,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":339,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/7d097c13c812eb6de553a301.png"},{"id":93610334,"identity":"69fc3976-c6c9-4a08-8e47-567a5e6aa4e2","added_by":"auto","created_at":"2025-10-15 16:09:46","extension":"wmf","order_by":20,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":380,"visible":true,"origin":"","legend":"","description":"","filename":"image3.wmf","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/44763853d39bbaa2b3bbf0e1.wmf"},{"id":93613297,"identity":"54c46794-2e43-4de8-a0e6-760c53ca95aa","added_by":"auto","created_at":"2025-10-15 16:25:45","extension":"png","order_by":21,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":36353,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/a069a4ce3f505e87b919cc60.png"},{"id":93614799,"identity":"6b57ed37-b89d-4c82-8732-9e5595de9c69","added_by":"auto","created_at":"2025-10-15 16:41:45","extension":"png","order_by":22,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":935,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/5024682df4525963cf8e1c44.png"},{"id":93612347,"identity":"aa6eb9a2-6aaf-4d3d-931f-c6e2ee626c27","added_by":"auto","created_at":"2025-10-15 16:17:46","extension":"png","order_by":23,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":406,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/f2bde1db98b968892ae63d73.png"},{"id":93610332,"identity":"01457dd7-e7e2-4c02-b7f9-d88f546ba31f","added_by":"auto","created_at":"2025-10-15 16:09:45","extension":"png","order_by":24,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":292,"visible":true,"origin":"","legend":"","description":"","filename":"Onlineimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/4cc75b6dbec447a9bf7ca18a.png"},{"id":93610336,"identity":"4828f4e0-02c4-4606-a28d-d0797aa76642","added_by":"auto","created_at":"2025-10-15 16:09:46","extension":"xml","order_by":25,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":123264,"visible":true,"origin":"","legend":"","description":"","filename":"a6c1c06e9fc94104b0ca87cad3dcdcb41structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/d9d50b25cb1da0e80d4df957.xml"},{"id":93610337,"identity":"1d3ad66a-a803-44f0-8006-43f840e2bc92","added_by":"auto","created_at":"2025-10-15 16:09:46","extension":"html","order_by":26,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":137166,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/623fc0d34f19d84a086ef354.html"},{"id":93610313,"identity":"7bcd869a-1633-4647-97df-df10fd533d11","added_by":"auto","created_at":"2025-10-15 16:09:45","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":85078,"visible":true,"origin":"","legend":"\u003cp\u003eConsolidated standards of reporting trials (CONSORT) participant flow diagram\u003c/p\u003e","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/e66769eed0f2590555cb4632.jpg"},{"id":99257222,"identity":"1e0cfba8-a68d-453d-9064-b2a2cc6fac70","added_by":"auto","created_at":"2025-12-30 23:08:46","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1668902,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7299984/v1/eea0780b-75e9-4850-b30c-fccfc26a1092.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"The Effect of Education and Telephone Follow-up Provided to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-Care Agency","fulltext":[{"header":"Introduction","content":"\u003cp\u003eIn recent years, studies aimed at understanding the relationship between the immune system and cancer have led to an increase in the use of cancer immunotherapy.\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e Immunotherapy, which is used in various types of metastatic cancer, has revolutionized cancer treatment with its lasting clinical results.\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e Today, there are numerous approved immunotherapy drugs for cancer treatment. These include immune checkpoint inhibitors (ICI), lymphocyte-regulating cytokines, chimeric antigen receptor therapy, and cancer vaccines.\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eCheckpoint inhibitors, which play a role in regulating the immune system, suppress the T cell response. This prevents autoimmunity and excessive inflammation, thereby maintaining homeostasis.\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e Tumor cells can use these immune checkpoints to suppress the T cell response and evade the immune system. At this stage, checkpoint inhibitors, whose clinical use is increasingly widespread, come into play. ICIs are used in various malignancies such as melanoma, lung cancer, and lymphoma.\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e ICIs, which eliminate tumor cells by regulating the immune response, can also cause immune-related adverse events (irAEs) that can affect many organs.\u003c/p\u003e\u003cp\u003eThese side effects may manifest as fatigue, itching, rash, redness, diarrhea, nausea, headache, and others. \u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e,\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e,\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e The timing of side effects varies depending on the affected organ and the type of treatment. Side effects may appear as early as the day after a single dose of medication or may occur weeks to months later.\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eIf these immune-related adverse events are not detected and managed early, they may lead to discontinuation of treatment and initiation of immunosuppressive therapy. Therefore, it is essential to identify the symptoms observed in patients receiving ICI therapy to strengthen symptom management.\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e A study evaluating the suitability, readability, quality, and usefulness of online resources for cancer patients receiving immunotherapy noted that there is a lack of resources to support patients in learning to manage immunotherapy side effects on their own. Additionally, brochures or booklets were found to be superior to web pages in terms of suitability and quality.\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eA qualitative study by Lai Kwon and colleagues on metastatic non-small cell lung cancer patients receiving immunotherapy identified unmet needs such as difficulties in managing treatment side effects and toxicity.\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eA review of the literature reveals that there are limited studies on symptom management in cancer patients receiving immune checkpoint inhibitor therapy.\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e,\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e For this reason, our study collected qualitative data from cancer patients only receiving checkpoint inhibitors to perform a needs analysis. An educational booklet was created based on the identified needs.This is because no studies evaluating symptoms and self-care agency in cancer patients receiving only immunotherapy have been found in the literature. Accordingly, this study aimed to determine the effect of education and telephone follow-ups provided to cancer patients receiving immune checkpoint inhibitor therapy on symptom management and self-care agency.\u003c/p\u003e\n\u003ch3\u003eStudy Purpose\u003c/h3\u003e\n\u003cp\u003eThe purpose of the study is to evaluate the effect of education and telephone follow-up provided to cancer patients who will receive checkpoint inhibitor treatment for the first time on symptom management and self-care agency.\u003c/p\u003e"},{"header":"Methods","content":"\u003ch2\u003eDesign\u003c/h2\u003e\u003cp\u003eIt is a randomized controlled trial designed by CONSORT (Consolidated Standards of Reporting Trials) recommendations, with a follow-up period of three months.\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e Trial registration: ClinicalTrials.gov NCT05683652.\u003c/p\u003e\u003ch3\u003eParticipants\u003c/h3\u003e\u003cp\u003eThe study was conducted in the outpatient chemotherapy unit of an educational research hospital in Turkey. Data for the study were collected between April 2022 and April 2023. The eligibility criteria were as follows: able to read and write Turkish, no psychiatric diagnosis that would impair comprehension, no physical impairment in hearing or speech that would prevent telephone communication, aware of receiving immunotherapy, receiving ICI therapy for the first time and only, aged 18–90, willing and eager to participate in the study, and participants who gave written and verbal consent to participate in the study. Exclusion criteria include: participants who wish to withdraw from the study, participants who cannot be reached or with whom communication is not possible, participants who die during the study, participants who receive radiotherapy or chemotherapy in addition to immunotherapy during the study, and participants who discontinue immunotherapy and switch to radiotherapy, chemotherapy, or other treatments.\u003c/p\u003e\u003ch3\u003eStudy procedure\u003c/h3\u003e\u003cp\u003eDuring the preparatory phase of the study, qualitative data was collected from patients only receiving ICI treatment. The purpose of conducting qualitative interviews was to establish the theoretical framework of the educational booklet based on patient experiences. Face-to-face interviews with 22 cancer patients receiving only ICI treatment were recorded and transcribed into written text by the researcher using Microsoft Office Word without any comments or additions. The data obtained were analyzed by the consultant and researcher using content analysis. After the data converted into written text were read repeatedly, the statements were coded. Thematic coding was performed on the responses to create main themes and subthemes. The themes and subthemes created were evaluated by obtaining expert opinion. A total of 3 main themes and 11 sub-themes were created. Here, the educational booklet was evaluated by experts according to the DISCERN (Quality Criteria for Consumer Health Information) scale in terms of content, appropriateness, reliability, and information quality, and the necessary adjustments were made.\u003c/p\u003e\u003ch3\u003eRandomization and Blinding\u003c/h3\u003e\u003cp\u003e After providing written informed consent, participants were assigned to the intervention and control groups according to the randomization list. The group assignment of participants was determined digitally (via WhatsApp) by a clerk responsible for treatment planning at the clinic, who was unaware of the study, based on the order of patient arrival. Due to the nature of the study, which included education and telephone follow-up, blinding of the researchers and participants was not possible. Data entry and analysis were performed by a statistician, and blinding was performed in the statistical analysis because the groups were only identified by numbers.\u003c/p\u003e\u003cp\u003eAdditionally, to prevent patient interaction, nurses working at the outpatient clinic were informed about the study, and patients in the intervention and control groups included in the study were treated on different days.\u003c/p\u003e\u003ch2\u003eOutcome Measures\u003c/h2\u003e\u003ch2\u003eDemographic and Medical Characteristics and Patient Information Form\u003c/h2\u003e\u003cp\u003eThe medical and demographic characteristics of patients were determined using a patient information form consisting of a total of eight questions prepared by the literature.\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e,\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003ch3\u003eTelephone Interview Form\u003c/h3\u003e\u003cp\u003e The researcher's telephone number was provided to participants in the intervention group so that they could contact the researcher when needed. No special line was set up for the study. Participants were informed that they could contact the researcher 24/7, and no time restrictions were imposed. The form includes the date of the conversation with the patient/relative, the reason for the conversation, its duration, the symptoms experienced, and recommendations.\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003ch2\u003eTelephone Interview Evaluation Form\u003c/h2\u003e\u003cp\u003eThis form was prepared for the purpose of evaluating telephone interviews conducted with participants in the intervention group.\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e The form, consisting of a total of five items, was administered to the intervention group at the end of the third session.\u003c/p\u003e\u003ch2\u003eNightingale Symptom Assessment Scale (N-SAS)\u003c/h2\u003e\u003cp\u003eThe scale is a well-being scale developed for cancer patients. In this study, it was used to identify symptoms developed by cancer patients undergoing immunotherapy about their disease and treatment. The scale is a five-point likert scale, where responses to the evaluated item are scored as “0” for “no,” “1” for “very little,” “2” for “some,” “3” for “quite a bit,” and ‘4’ for “very much.” A high score on the scale indicates that the patient is highly affected by disease/treatment-related problems, while low scores indicate that patients have low overall quality of life and well-being in terms of subdimensions.\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e In the study, the Cronbach's alpha reliability coefficient of the scale was found to be 0.90.\u003c/p\u003e\u003ch2\u003eSelf-Care Agency Scale (SCAS)\u003c/h2\u003e\u003cp\u003eThe scale focuses on individuals' self-assessments of their engagement in self-care activities. The scale consists of 35 items, each of which is scored from 0 to 4. The response options are as follows: “Does not describe me at all” is scored as 0, “Does not describe me much” is scored as 1, “I don't know” is scored as 2, “Describes me a little” is scored as 3, and “Describes me very much” is scored as 4.\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e In our study, the Cronbach alpha reliability coefficient of the scale was found to be 0.95.\u003c/p\u003e\u003ch2\u003eData Collection Procedure\u003c/h2\u003e\u003cp\u003eParticipants were selected based on inclusion and exclusion criteria and were provided with detailed information about the study. Participants were asked to sign a written informed consent form. Each participant was assigned a numerical code. Patients in the intervention group were contacted according to a list generated by Random.org, and an appointment was scheduled one hour before their first immunotherapy session. The interviews were conducted in a quiet, isolated room with a table and chairs, which was a passive area within the unit where there was no patient flow. Patients and their relatives were included in the training. The training sessions lasted an average of 40–50 minutes. Patients in the intervention group who received training were followed up by telephone by the researcher within one week after each course. During the telephone calls, symptom monitoring was performed, and coping strategies for reported symptoms were reviewed. Routine clinical procedures were applied to patients in the control group. The first measurements for patients in both groups were taken in person on the day they came for their second course of treatment, and the second measurements were taken in person after the third course of treatment was completed.\u003c/p\u003e\u003ch2\u003eStatistical Methods\u003c/h2\u003e\u003cp\u003eAll data were analyzed using IBM SPSS Statistics version 23.0 (IBM Corp Armonk, NY). The number, percentage, mean, standard deviation, and chi-square test were used to evaluate the participants' demographic and medical characteristics. The t-test for independent samples was used to determine the difference between groups according to age. The Mann-Whitney U test was used to determine whether there were differences between groups in terms of N-SAS and SCAS scores, and the Wilcoxon matched-pairs test was used to determine differences between measurement times for N-SAS and SCAS scores. Cohen's d values were used to interpret the effect size (G) of the education provided and telephone follow-up.\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e P \u0026lt; .05 was considered statistically significant.\u003c/p\u003e\u003ch2\u003eEthical Considerations\u003c/h2\u003e\u003cp\u003e This study was approved by the Ethics Committee of Ankara Yıldırım Beyazıt University Faculty of Social and Human Sciences (E-84892257-300-100327). After the necessary explanations about the study were made to the participants included in the study, both verbal and written consent forms were obtained from all participants in accordance with the Declaration of Helsinki.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eA total of 74 participants were screened. Two participants who met the sample criteria declined to participate in the study, so 72 participants were randomized. One participant from the control group and one participant from the intervention group were excluded. One participant was also excluded from the study because radiotherapy was added to their treatment. The study was completed with a total of 69 participants, 34 in the intervention group and 35 in the control group.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eParticipants\u0026rsquo; Characteristics\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThere was no statistically significant difference between the intervention and control groups in terms of personal and medical information. The groups were found to be homogeneously distributed (Table 1). The participants most commonly had a diagnosis of lung cancer, had previously undergone chemotherapy, were in stage IV, and had hypertension as the most common accompanying chronic disease (Table 1).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEffects of the Intervention\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll participants in the intervention group reported satisfaction with the telephone calls and stated that the calls helped them cope with the side effects of immunotherapy (Table 2). The most common symptoms reported by participants in the intervention group following telephone follow-up were fatigue, constipation, itching, dry mouth, dry skin, decreased appetite, and coughing (Table 3).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 4 shows that the median self-care strength value measured at the end of the third cycle was 115.0 (103-121) in the intervention group and 75.0 (63-90) in the control group, and the difference between the two groups was statistically significant (p\u0026lt;0.05). When looking at the median values, the median value of SCAS \u0026nbsp;in the intervention group was higher than that in the control group. This indicates that the self-care agency of participants in the intervention group was at a better level than that of the control group at the end of the third cycle. The effect of the education and telephone follow-up applied to the intervention group on self-care agency at the second measurement (end of the third session) was found to be strong (G=1.78).\u003c/p\u003e\n\u003cp\u003eThe median value of the N-SAS physical well-being subscale score for the intervention group was 0.08 (0-0.20), while the median value of the N-SAS physical well-being subscale score for the control group was 0.30 (0.20-0.65), and the difference between the two was statistically significant (p\u0026lt;0.05). When looking at the median values, the median value of the physical well-being subscale score in the control group is higher than that in the intervention group. This indicates that the physical well-being of the participants in the intervention group was at a better level than that of the control group at the end of the third session. The education and telephone follow-up applied to the intervention group were found to have a strong effect on physical well-being at the second measurement (end of the third session) (G=1.03).\u003c/p\u003e\n\u003cp\u003eThe median value of the N-SAS social well-being subscale score for the intervention group was 0 (0-0), while the median value of the N-SAS social well-being subscale score for the control group was 0.13 (0-0.25), and the difference between the two was statistically significant (p\u0026lt;0.05). When looking at the median values, the median value of the social well-being subscale score of the control group is higher than that of the intervention group. This indicates that the social well-being of the participants in the intervention group was at a better level than that of the control group at the end of the third session. It was determined that the education and telephone follow-up applied to the intervention group had a strong effect on social well-being at the second measurement (end of the third session) (G = 0.86).\u003c/p\u003e\n\u003cp\u003eThe median value of the N-SAS psychological well-being subscale score for the intervention group was 0.20 (0-0.70), while the median value of the N-SAS psychological well-being subscale score for the control group was 0.40 (0-0.90), and the difference between the two was not statistically significant (p\u0026gt;0.05).\u003c/p\u003e\n\u003cp\u003eThe median value of the N-SAS score for the intervention group was 0.14 (0.04-0.28), while the median value of the N-SAS score for the control group was 0.34 (0.17-0.58), and the difference between the two was statistically significant (p\u0026lt;0.05). When looking at the median values, the median value of the N-SAS score in the control group is higher than that in the intervention group. This indicates that the participants in the intervention group had a better level of general well-being at the end of the third session compared to the control group. The education and telephone follow-up applied to the intervention group were found to have a moderate effect on general well-being at the second measurement (end of the third session) (G=0.55).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eReviews and guidelines on cancer patients receiving immunotherapy in the literature indicate that patients should be informed about possible side effects and that early detection and reporting of these side effects is important for symptom.\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e,\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e,\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e In an observational retrospective study evaluating nurse-led telephone follow-up over a six-month period for palliative care patients with advanced cancer, it was determined that telephone follow-up can be effective for patients and their families by improving symptom control.\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e In line with the literature, this study found that the education and telephone follow-up provided to the intervention group improved participants' physical and social well-being. The significant difference observed in the physical well-being subscale may be related to the fact that the educational content focused more on the management of physical symptoms. Based on the feedback from participants in the intervention group who received telephone follow-up, it appears that simply calling them and asking about their well-being made them happy and suggests that the social well-being of participants in the intervention group was at a higher level than that of the control group. Furthermore, it is thought that the lack of focus on the management of psychological symptoms in the educational content provided to the intervention group did not create a statistically significant difference between the groups in terms of psychological well-being and had a weak effect.\u003c/p\u003e\u003cp\u003eIn a study examining the effect of education provided to patients undergoing inpatient treatment for laryngeal cancer on self-care agency, it was noted that the group that received education had a better level of self-care agency.\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e Another study examining the effect of web-based education on self-care behaviors and social adjustment in cancer patients determined that the education provided could improve patients' self-care agency and self-management behaviors.\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e In this study, it is thought that the education and telephone follow-up applied to the intervention group increased the participants' self-care capacity and that the education provided during the telephone follow-ups after the face-to-face education created a significant difference between the first and second measurements due to the repetition of the education when necessary.\u003c/p\u003e\u003cdiv id=\"Sec21\" class=\"Section2\"\u003e\u003ch2\u003eStudy limitations\u003c/h2\u003e\u003cp\u003eThe study was limited by the fact that it was conducted in a specific patient group that only received immune checkpoint inhibitors, the number of patients who would only receive ICIs was small, losses occurred in the sample group during the study, and the fact that randomization could not be double-blind due to the nature of the study.\u003c/p\u003e\u003c/div\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIt was determined that the effect of education and telephone monitoring given to cancer patients receiving immunotherapy on self-care capacity was at a strong level, and its effect on symptom management was at a medium level. Therefore, telephone monitoring together with education in patients receiving immune checkpoint inhibitors has an effect on both symptom management and increasing self-care agency.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eAUTHOR CONTRIBUTIONSGamze ALINCAK: Data curation, Formal analysis, Writing- original draft, Investigation, Ayşeg\u0026uuml;l KO\u0026Ccedil;: Formal analysis, Writing- original draft, Investigation,\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eFunding Declarations\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003e\u003cstrong\u003eGupta, S., Gupta, S. C., Hunter, K. D., \u0026amp; Pant, A. B. (2020). \u003c/strong\u003eImmunotherapy: a new hope for cancer patients. \u003cem\u003eJournal of Oncology\u003c/em\u003e, 3548603.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eZhang, Y., \u0026amp; Zhang, Z. (2020).\u003c/strong\u003e The history and advances in cancer immunotherapy: understanding the characteristics of tumor‑infiltrating immune cells and their therapeutic implications. \u003cem\u003eCellular \u0026amp; Molecular Immunology\u003c/em\u003e, 17(8), 807‑821.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003ePassarelli, A., Mannavola, F., Stucci, L. S., Tucci, M., \u0026amp; Silvestris, F. (2017).\u003c/strong\u003e Immune system and melanoma biology: a balance between immunosurveillance and immune escape. \u003cem\u003eOncotarget\u003c/em\u003e, 8(62), 106132.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eBagchi, S., Yuan, R., \u0026amp; Engleman, E. G. (2021).\u003c/strong\u003e Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. \u003cem\u003eAnnual Review of Pathology\u003c/em\u003e, 16, 223\u0026ndash;249.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eKennedy, L. B., \u0026amp; Salama, A. K. (2020).\u003c/strong\u003e A review of cancer immunotherapy toxicity. \u003cem\u003eCA: A Cancer Journal for Clinicians\u003c/em\u003e, 70(2), 86\u0026ndash;104.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eArnaud‑Coffin, P., Maillet, D., Gan, H. K., Stelmes, J. J., You, B., Dalle, S., \u0026amp; P\u0026eacute;ron, J. (2019).\u003c/strong\u003e A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. \u003cem\u003eInternational Journal of Cancer\u003c/em\u003e, 145(3), 639‑648.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eBrahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., \u0026amp; Hallmeyer, S. (2018).\u003c/strong\u003e Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. \u003cem\u003eJournal of Clinical Oncology\u003c/em\u003e, 36(17), 1714.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eDurrechou, Q., Domblides, C., Sionneau, B., Lefort, F., Quivy, A., Ravaud, A., Gross‑Goupil, M., \u0026amp; Daste, A. (2020).\u003c/strong\u003e Management of immune checkpoint inhibit\u0026ouml;r toxicities. \u003cem\u003eCancer Management and Research\u003c/em\u003e, 9139‑9158.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eSznol, M., Postow, M. A., Davies, M. J., Pavlick, A. C., Plimack, E. R., Shaheen, M., Veloski, C., \u0026amp; Robert, C. (2017).\u003c/strong\u003e Endocrine‑related adverse events associated with immune checkpoint blockade and expert insights on their management. \u003cem\u003eCancer Treatment Reviews\u003c/em\u003e, 58, 70‑76.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eFeng, L. N., He, J., Feng, L. X., Li, Y., Li, J., \u0026amp; Chen, C. (2023).\u003c/strong\u003e Symptoms, symptom clusters and associated factors among cancer patients receiving immune checkpoint inhibitor therapy: A cross-sectional survey. \u003cem\u003eEuropean Journal of Oncology Nursing\u003c/em\u003e, 63, 102288.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eNicolas‑Joseph, M., Brahim, L. O., Boureanu, M. I., Frati, F. Y., Bourdache, L. R., Belzile, E., \u0026amp; Lambert, S. D. (2023).\u003c/strong\u003e An evaluation of the suitability, readability, quality, and usefulness of online resources for patients with cancer receiving immunotherapy. \u003cem\u003ePatient Education and Counseling\u003c/em\u003e, 110, 107640.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eLai‑Kwon, J., Heynemann, S., Flore, J., Dhillon, H., Duffy, M., Burke, J., \u0026hellip; Jefford, M. (2021).\u003c/strong\u003e Living with and beyond metastatic non‑small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. \u003cem\u003eJournal of Cancer Survivorship\u003c/em\u003e, 15, 392‑397.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eGlaser, S. L. C., Fraterman, I., van Brummelen, N., Tibollo, V., Del Campo, L. M., Mallo, H., \u0026hellip; Medlock, S. (2025).\u003c/strong\u003e Usability and Usefulness of a Symptom Management Coaching System for Patients With Cancer Treated With Immune Checkpoint Inhibitors: Comparative Mixed Methods Study. \u003cem\u003eJMIR Formative Research\u003c/em\u003e, 9, e57659.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eKutzleben, M. V., Galuska, J. C., Hein, A., Griesinger, F., \u0026amp; Ansmann, L. (2022).\u003c/strong\u003e Needs of Lung Cancer Patients Receiving Immunotherapy and Acceptance of Digital and Sensor-Based Scenarios for Monitoring Symptoms at Home\u0026mdash;A Qualitative‑Explorative Study. \u003cem\u003eInternational Journal of Environmental Research and Public Health\u003c/em\u003e, 19(15), 9265.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eGewandter, J. S., Eisenach, J. C., Gross, R. A., et al. (2019).\u003c/strong\u003e Checklist for the preparation and review of pain clinical trial publications: a pain-specific supplement to CONSORT. \u003cem\u003ePain Reports\u003c/em\u003e, 4(3):38\u0026ndash;40.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eReam, E., Hughes, A. E., Cox, A., Skarparis, K., Richardson, A., Pedersen, V. H., \u0026amp; Bryant, A. (2020).\u003c/strong\u003e Telephone interventions for symptom management in adults with cancer. \u003cem\u003eCochrane Database of Systematic Reviews\u003c/em\u003e, 6.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eTatokoro, M., \u0026amp; Matsuo, N. (2022).\u003c/strong\u003e The Impact of Aging on Symptom Prevalence and Management in Terminally ill Patients With Cancer. \u003cem\u003eJournal of Pain and Symptom Management\u003c/em\u003e, 63(2), 251‑259.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003e\u0026Ouml;kten, \u0026Ccedil;. (2017).\u003c/strong\u003e Kemoterapi uygulanan kolorektal kanserli hastalarda orem \u0026ouml;z bakım eksikliği kuramına temellendirilmiş eğitimin ve telefonla izlemin \u0026ouml;z bakım g\u0026uuml;c\u0026uuml;, kaygı, yalnızlık ve iyilik hallerine etkisi (Doktora tezi). Akdeniz \u0026Uuml;niversitesi.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eCan, G., Erol, O., Aydiner, A., \u0026amp; Topuz, E. (2011).\u003c/strong\u003e Non-pharmacological interventions used by cancer patients during chemotherapy in Turkey. \u003cem\u003eEuropean Journal of Oncology Nursing\u003c/em\u003e, 15(2), 178\u0026ndash;184.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eNahcivan, N. O. (2004).\u003c/strong\u003e A Turkish language equivalence of the exercise of self-care agency scale. \u003cem\u003eWestern Journal of Nursing Research\u003c/em\u003e, 26(7), 813‑824.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eBerk, İ. (2019).\u003c/strong\u003e Meta Analizi: Paralel Kontroll\u0026uuml; \u0026Ccedil;alışmalarda Bir Uygulama (Y\u0026uuml;ksek Lisans Tezi). Afyon Kocatepe \u0026Uuml;niversitesi.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eSchneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., \u0026amp; Davies, M. J. (2021).\u003c/strong\u003e Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. \u003cem\u003eJournal of Clinical Oncology\u003c/em\u003e, 39(36), 4073‑4126.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eWood, L. S., Moldawer, N. P., \u0026amp; Colleen Lewis, M. S. N. (2019).\u003c/strong\u003e Immune checkpoint inhibitor therapy. \u003cem\u003eClinical Journal of Oncology Nursing\u003c/em\u003e, 23(3), 271‑280.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eZhang, L., \u0026amp; Lu, Y. (2021).\u003c/strong\u003e Follow-up care for patients receiving immune checkpoint inhibitors. \u003cem\u003eAsia‑Pacific Journal of Oncology Nursing\u003c/em\u003e, 8(6), 596‑603.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eValenti, V., Rossi, R., Scarpi, E., Ricci, M., Pallotti, M. C., Dall\u0026rsquo;Agata, M., Montalti, S., \u0026amp; Maltoni, M. (2023).\u003c/strong\u003e Nurse‑led telephone follow‑up for early palliative care patients with advanced cancer. \u003cem\u003eJournal of Clinical Nursing\u003c/em\u003e, 32(11‑12), 2846‑2853.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eFırat, S., \u0026amp; \u0026Ouml;ztun\u0026ccedil;, G. (2019).\u003c/strong\u003e Total larenjektomili hastalara verilen eğitimin \u0026ouml;z bakım g\u0026uuml;c\u0026uuml;ne etkisi. \u003cem\u003e\u0026Ccedil;ukurova Medical Journal\u003c/em\u003e, 44(3), 911‑921.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eFeng, L., Wang, W., Wu, M., \u0026amp; Ma, H. (2021). \u003c/strong\u003eEffect of WeChat‐Based Health Education Combined with Satir Model on Self‐Management Behaviors and Social Adaptation in Colorectal Cancer Patients during the Perioperative Period. \u003cem\u003eJournal of Healthcare Engineering\u003c/em\u003e, \u003cem\u003e2021\u003c/em\u003e(1), 2701039.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003e\u003cem\u003eTable 1. Group Comparison of Demographic and Medical Characteristics of Participants in the Intervention and Control Groups\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"538\" height=\"709\"\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTable 2. Distribution of Responses of Participants in the Intervention Group to the Telephone Interview Evaluation Form\u003c/em\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" align=\"\" width=\"556\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 337px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTelephone Interview Evaluation Form\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 219px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eIntervention Group (n=34)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e%\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 337px;\"\u003e\n \u003cp\u003eHow phone calls can help you cope with immunotherapy side effects\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eYes it helped\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e100,0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eSatisfaction with phone calls\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eYes, I\u0026apos;m satisfied.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e100,0\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eThere is a situation that prevents you from making a phone call.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eYes it happened.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e5,9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eNo it didn\u0026apos;t happen.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e94,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eVisiting any healthcare institution other than routine check-ups due to immunotherapy-related side effects in the last 3 months\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eYes I applied\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e26,5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eNo I did not apply\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e73,5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 337px;\"\u003e\n \u003cp\u003eReason for applying to the health institution for applicants\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eBloody sputum\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e11,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003ePain and swelling in joints\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e11,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eChest pain\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e11,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eCough, Fatigue\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e11,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eCough, Dispnea\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e11,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eIncreased fever\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e11,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eDizziness, Vomiting\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e11,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eTingling in the fingers\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e11,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eForgetfulness, absent-mindedness, inability to form sentences\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e11,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eWhat happened to the applicants?\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eHospitalization drug therapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e44,4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eRheumatology Polyclinic\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e11,2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eEmergency Unit\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e22,2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 337px;\"\u003e\n \u003cp\u003eNeurology Polyclinic\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 128px;\"\u003e\n \u003cp\u003e22,2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cem\u003eTable3 .Distribution of symptoms determined by telephone in the intervention group\u003c/em\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"529\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 347px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eIntervention Group (n = 34)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 183px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSymptom\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 173px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eYes\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 173px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNo\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003en\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003en\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eFatigue\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e70,6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e29,4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eConstipation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e41,2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e58,8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eItching\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e38,2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e61,8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eDryness on the mouth\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e32,4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e67,6\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eSkin dryness\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e26,5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e73,5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eLoss appetite\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e20,6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e79,4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eCough\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e14,7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e85,3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eShortness of breath\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e8,8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e91,2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eVomiting\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e8,8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e91,2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eExchange of taste\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e8,8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e91,2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eRedness on the skin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e5,9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e94,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eRedness of the eye\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e5,9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e94,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eHigh fever\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e5,9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e94,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eDiarrhea\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e2,9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e97,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eBloody sputum\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e2,9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e97,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eSwelling in the joints\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e2,9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e97,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eIncrease Blood pressure\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e2,9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e97,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eNight sweating\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e2,9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e97,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eJaundice in the hands\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e2,9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e97,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eChest pain\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e2,9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e97,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 183px;\"\u003e\n \u003cp\u003eTingle\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e2,9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003e97,1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cem\u003eTable 4. Comparison of Self-Care Abilities Scale and Nightingale Symptom Assessment Scale (N-SAS) and Sub-Dimension Scores of Groups According to the Second Measurement Time\u003c/em\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"627\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 78px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eScales and Subdimensions\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 67px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 31px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMin.\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 38px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMaks.\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" valign=\"bottom\" style=\"width: 41px;\"\u003e\n \u003cp\u003e\u003cbr\u003e\u003cimg width=\"14\" src=\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABcAAAAfCAMAAAA7p6b/AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAA2UExURQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAALd2aHIAAAASdFJOUwD/c0yhDI3KGexYvN0xqT1kSt+jppIAAAAJcEhZcwAAFxEAABcRAcom8z8AAACISURBVChTxZDBEsMgCEQXUaIV0+b/f7YTNDNKzmnfRV11WQD+CC34298TehAG4lgHSYi2fO64SJq/vMYzCbNqXjUBLE5GVgpo+2JiMJX33rwKy+LNjaxTwomspJbVIZ9K0YsAh7P0rbBFjNbETLKI1sQiS4/inI5N+7EpleNSU72m2wfuazzBF9NzAq5g43JnAAAAAElFTkSuQmCC\" alt=\"image\" height=\"19\"\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSS\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 48px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMedian\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e95,0% CL\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eQuarterly Slice\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 37px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eZ\u003csup\u003e1\u003c/sup\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 46px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 57px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCohen\u0026rsquo;s d\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eLower-Upper\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e25-75p\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 78px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSelf Care Agency Scale\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67px;\"\u003e\n \u003cp\u003eExperimental\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e66\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38px;\"\u003e\n \u003cp\u003e134\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 41px;\"\u003e\n \u003cp\u003e111,2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 33px;\"\u003e\n \u003cp\u003e15,8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 48px;\"\u003e\n \u003cp\u003e115\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e113,00-119,00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e103,00-121,00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 37px;\"\u003e\n \u003cp\u003e-5,46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 46px;\"\u003e\n \u003cp\u003e\u0026lt;0,001*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 33px;\"\u003e\n \u003cp\u003e1,78\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 57px;\"\u003e\n \u003cp\u003eStrongly\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 67px;\"\u003e\n \u003cp\u003eControl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38px;\"\u003e\n \u003cp\u003e125\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 41px;\"\u003e\n \u003cp\u003e77,4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 33px;\"\u003e\n \u003cp\u003e21,7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 48px;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e67,00-83,00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e63,00-90,00\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 78px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN-SAS\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003ePhysical Well-Being\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67px;\"\u003e\n \u003cp\u003eExperimental\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38px;\"\u003e\n \u003cp\u003e0,95\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 41px;\"\u003e\n \u003cp\u003e0,16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 33px;\"\u003e\n \u003cp\u003e0,21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 48px;\"\u003e\n \u003cp\u003e0,08\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e0,05-0,15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e0-0,20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 37px;\"\u003e\n \u003cp\u003e-4,23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 46px;\"\u003e\n \u003cp\u003e\u0026lt;0,001*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 33px;\"\u003e\n \u003cp\u003e1,03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 57px;\"\u003e\n \u003cp\u003eStrongly\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 67px;\"\u003e\n \u003cp\u003eControl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38px;\"\u003e\n \u003cp\u003e1,5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 41px;\"\u003e\n \u003cp\u003e0,44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 33px;\"\u003e\n \u003cp\u003e0,33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 48px;\"\u003e\n \u003cp\u003e0,3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e0,25-0,65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e0,20-0,65\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 78px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN-SAS\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eSocial Well-Being\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67px;\"\u003e\n \u003cp\u003eExperimental\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38px;\"\u003e\n \u003cp\u003e0,38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 41px;\"\u003e\n \u003cp\u003e0,04\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 33px;\"\u003e\n \u003cp\u003e0,09\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 48px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e0-0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 37px;\"\u003e\n \u003cp\u003e-3,38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 46px;\"\u003e\n \u003cp\u003e\u0026lt;0,001*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 33px;\"\u003e\n \u003cp\u003e0,86\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 57px;\"\u003e\n \u003cp\u003eStrongly\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 67px;\"\u003e\n \u003cp\u003eControl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38px;\"\u003e\n \u003cp\u003e0,75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 41px;\"\u003e\n \u003cp\u003e0,18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 33px;\"\u003e\n \u003cp\u003e0,2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 48px;\"\u003e\n \u003cp\u003e0,13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e0-0,25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e0-0,25\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 78px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN-SAS\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003ePsychological Well-Being\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67px;\"\u003e\n \u003cp\u003eExperimental\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38px;\"\u003e\n \u003cp\u003e2,8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 41px;\"\u003e\n \u003cp\u003e0,52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 33px;\"\u003e\n \u003cp\u003e0,77\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 48px;\"\u003e\n \u003cp\u003e0,2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e0-0,40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e0-0,70\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 37px;\"\u003e\n \u003cp\u003e-1,24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 46px;\"\u003e\n \u003cp\u003e0,216\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 33px;\"\u003e\n \u003cp\u003e0,2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 57px;\"\u003e\n \u003cp\u003eWeakly\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 67px;\"\u003e\n \u003cp\u003eControl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38px;\"\u003e\n \u003cp\u003e3,2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 41px;\"\u003e\n \u003cp\u003e0,67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 33px;\"\u003e\n \u003cp\u003e0,79\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 48px;\"\u003e\n \u003cp\u003e0,4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e0,30-0,90\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e0-0,90\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 78px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNightingale Symptom Assessment Scale (N-SAS)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67px;\"\u003e\n \u003cp\u003eExperimental\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38px;\"\u003e\n \u003cp\u003e1,22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 41px;\"\u003e\n \u003cp\u003e0,24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 33px;\"\u003e\n \u003cp\u003e0,31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 48px;\"\u003e\n \u003cp\u003e0,14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e0,08-0,18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e0,04-0,28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 37px;\"\u003e\n \u003cp\u003e-2,98\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 46px;\"\u003e\n \u003cp\u003e0,003*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 33px;\"\u003e\n \u003cp\u003e0,55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 57px;\"\u003e\n \u003cp\u003eModerately\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 67px;\"\u003e\n \u003cp\u003eControl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e0,03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38px;\"\u003e\n \u003cp\u003e1,82\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 41px;\"\u003e\n \u003cp\u003e0,43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 33px;\"\u003e\n \u003cp\u003e0,39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 48px;\"\u003e\n \u003cp\u003e0,34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 54px;\"\u003e\n \u003cp\u003e0,22-0,52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e0,17-0,58\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e**p\u0026lt;0.05; Z1: Mann Whitney U test, 95% CI Lower-Upper: Lower limit-Upper limit in the 95% confidence interval; Quartile, 25-75p: 25th and 75th quartiles, G: Effect Size\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-7299984/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7299984/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eObjective: \u003c/strong\u003eThis study aimed to evaluate the effect of education and telephone follow-up provided to cancer patients receiving immunotherapy on symptom management and self-care agency.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods: \u003c/strong\u003eThe data for this study were collected from the outpatient chemotherapy unit of an educational research hospital. The study sample consisted of cancer patients who agreed to participate in the study and who were receiving immunotherapy for the first time and exclusively (n=69). In the first phase of the study, interviews were conducted with 22 cancer patients receiving immunotherapy to develop the content of the educational booklet. Participants were divided into an intervention group (n=34) and a control group (n=35) using a randomization list. Participants in the intervention group received face-to-face education using the developed educational booklet and were followed up by telephone for three months. The control group received standard care. Participants in the intervention group were assessed twice after receiving the education: at the end of the first cycle and at the end of the third cycle. Demographic and medical characteristics were collected using a patient information form, telephone interview form, telephone interview evaluation form, Nightingale Symptom Assessment Scale, and Self-Care Agency Scale.\u003c/p\u003e\n\u003cp\u003eDescriptive statistics, chi-square, t-test for independent samples, Mann Whitney U test to examine differences in scale scores between groups, and Wilcoxon matched-pairs test to examine differences in scale scores between measurement times were used to evaluate the data.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults: \u003c/strong\u003eThe intervention significantly enhanced self-care capacity among patients receiving immunotherapy (p \u0026lt; 0.05, G = 1.78). Moreover, physical and social well-being scores were significantly higher in the intervention group compared to controls (p \u0026lt; 0.05).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusions: \u003c/strong\u003eEducation and telephone follow-up provided to cancer patients receiving immunotherapy were found to be effective in increasing patients' self-care capacity and managing possible symptoms (p\u0026lt;0.05, G=1.78, G=0.55).\u003c/p\u003e","manuscriptTitle":"The Effect of Education and Telephone Follow-up Provided to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-Care Agency","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-15 16:09:40","doi":"10.21203/rs.3.rs-7299984/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"48842773-9d03-4031-bc51-e08f2a75f069","owner":[],"postedDate":"October 15th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-12-30T23:08:27+00:00","versionOfRecord":[],"versionCreatedAt":"2025-10-15 16:09:40","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7299984","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7299984","identity":"rs-7299984","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}